Recombinant Rat Chemokine (C-C Motif) Ligand 5

• Cat.No.: Ccl5-104R
• Product Overview: Recombinant Rat RANTESproduced inE.coliis a 7.9 kDa protein containing 69 amino acid residues.

Specification

• Cat. No.: Ccl5-104R
• Description: RANTES is a protein which has been shown to be a chemoattractant for peripheral blood monocytes. It appears to selectively attract T cells of the CD4+/CD45RO+ phenotype in vitro.
• Source: E.coli.
• Purity: > 98% (SDS-PAGE; HPLC).
• Endotoxin level: < 0.1 ng/g of RANTES.
• Stabilizer: None.
• Formulation: Lyophilized.
• Biologically Activity: Rat RANTES produces chemotaxis over a wide concentration range in an assay using rat peritoneal macrophages. Significant chemotaxis was achieved using a concentration of 10-50 ng/ml.
• Reconstitution: The lyophilized RANTES is soluble in water and most aqueous buffers. The lyophilized powder should be reconstituted in water to a concentration of 100 ng/µl. It is recommended that further dilutions be made into buffer containing carrier protein or medium containing serum.
• Stability: The lyophilized powder, though stable at room temperature, is best stored desiccated below 0°C. Reconstituted RANTES should be stored in working aliquots at -20°C. Avoid repeated freeze-thaw cycles.
• Tag: Non

Gene Information

• Gene Name: Ccl5 chemokine (C-C motif) ligand 5 [ Rattus norvegicus ]
• Synonyms: Ccl5; chemokine (C-C motif) ligand 5; Scya5; Rantes; small inducible cytokine A5; RANTES; small inducible cytokine A5 (RANTES)
• Gene ID: 81780
• mRNA Refseq: NM_031116
• Protein Refseq: NP_112378
• UniProt ID: P50231
• Chromosome Location: q26
• Pathway: Chemokine signaling pathway; Cytokine-cytokine receptor interaction; Prion diseases; Toll-like receptor signaling pathway
• Function: chemoattractant activity; chemokine activity

Citation

Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5.

Journal: Journal of immunology (Baltimore, Md. : 1950)    PubMed ID: 22450806    Data: 2012/6/11

Authors: Nahzli Dilek, Nicolas Poirier, Bernard Vanhove

Article Snippet:ALZET osmotic mini-pumps (model 2001) were purchased from Charles River (Wilmington, MA).ALZET osmotic mini-pumps (model 2001) were purchased from Charles River (Wilmington, MA).. Filling osmotic pumps with recombinant rat CCL5 (Creative BioMart) was done according to the instructions of the manufacturer.. Pumps were surgically implanted i.p. under isoflurane anesthesia and sterile conditions.Pumps were surgically implanted i.p. under isoflurane anesthesia and sterile conditions.

Publication :

Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5 (2012)

Reviews

08/17/2021

This specificity enables precise quantification and characterization of CCL5 and its interactions with other molecules or proteins of interest.

06/23/2019

Its exceptional performance, coupled with its ability to generate clear and precise protein bands, make it an indispensable tool in achieving accurate and reliable results.

06/20/2016

The CCL5 protein exhibits a high degree of specificity in various assays, ensuring accurate and reliable results.

Q&As

What are the potential clinical applications of CCL5 inhibitors?

CCL5 inhibitors may be used to control inflammation in diseases like rheumatoid arthritis or as an adjuvant in cancer therapy.

Can CCL5 be used to stimulate the immune system in cancer treatment?

CCL5-based immunotherapies are being explored to enhance the immune response against cancer cells.

Can CCL5 be used as a diagnostic marker for diseases?

It can serve as a biomarker for some diseases, but it is usually used in conjunction with other markers for more accurate diagnostics.

What are the clinical implications of elevated CCL5 levels?

Elevated CCL5 levels are associated with inflammation and may be indicative of certain diseases such as rheumatoid arthritis or HIV infection.

Are there any CCL5-targeted therapies in development?

Yes, there are ongoing efforts to develop therapies that modulate CCL5 activity, particularly in diseases involving inflammation.